Targeting Mnks for Cancer Therapy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Jinqiang Hou 1 , Frankie Lam 1 , Christopher Proud 2 and Shudong Wang 1 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia 2 Centre for Biological Sciences, University of Southampton, Southampton, UK Received: February 16, 2012; Accepted: February 29, 2012; Published: March 3, 2012; Keywords: eIF4E, Mnk, Ras, Raf, MAPK, Akt, PI3K, mTOR, Targeted Cancer Therapy, Structure based drug design, Mnk Inhibitors Correspondence: Shudong Wang, // // Abstract Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · cited 15×
“Its loss results in activation of Akt and increases downstream mTORC1 signalling.”
BackgroundInfluentialUeda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., & Fukunaga, R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6539-6549.2004 · Cited by 507
Dissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487 · cited 3×
“Recent studies confirmed that phosphorylation of eIF4E at the Ser209 by Mnk is essential for eIF4E’s ability to promote tumourigenesis [72], while it is dispensable in normal tissue [21, 35, 54, 55, 72].”
BackgroundMethod
Cited by
Baell, J. B. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00947 · Cited by 539
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirovic, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 324
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
miR-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability
Sakai, A., Saitow, F., Miyake, N., Miyake, K., Shimada, T., & Suzuki, H. (2013) · Brain · doi:10.1093/brain/awt191 · Cited by 129
Beggs, J. E., Tian, S., Jones, G. G., Xie, J., Iadevaia, V., Jenei, V., Thomas, G., & Proud, C. G. (2015) · Biochemical Journal · doi:10.1042/bj20141066 · Cited by 65
Self-citation
Metadata
- Authors
- Hou, J., Lam, F., Proud, C., & Wang, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2012-02-29
- Volume
- 3
- Issue
- 2
- Pages
- 118-131
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2121647526
- Cited by
- 142
- References
- 4
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Mnks for Cancer Therapy. https://app.cochat.ai/papers/10.18632/oncotarget.453
- The paper
- Hou, J., Lam, F., Proud, C., & Wang, S. (2012). Targeting Mnks for Cancer Therapy. Oncotarget. https://doi.org/10.18632/oncotarget.453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.